| PATENT NUMBER | This data is not available for free |
| PATENT GRANT DATE | March 26, 2002 |
| PATENT TITLE |
Glial cell line-derived neurotrophic factor |
| PATENT ABSTRACT |
A novel neurotrophic factor referred to as glial derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process. |
| PATENT INVENTORS | This data is not available for free |
| PATENT ASSIGNEE | This data is not available for free |
| PATENT FILE DATE | May 26, 1995 |
| PATENT REFERENCES CITED |
Aebischer et al. (1991), `Long-Term Cross-Species Brain Transplantation of a Polymer-Encapsulated Dopamine-Secreting Cell Line`, Exper. Neurol., 111:269-275. Beltz et al. (1983) `Isolation of Multigene Families and Determination of Homologies by Filter Hybridization Methods`, Methods in Enzymology, 100:266-285. Bohn et al. (1989), The Development of Mesencephalic Dopaminergic Neurons in Vitro Is Affected by Neurotrophic Activities Derived From Neural Cell Line, Soc. Neurosci. Abs., 15:277. Collins (1978), `Axon Initiation by Ciliary Neurons in Culture`, Develop. Biol., 65:50-57. Dayhoff, in Atlas of Protein Sequence and Structure vol. 5, p. 124 (1972), National Biochemical Research Foundation, Washington, D.C. Friedman et al. (1987), `The toxicity of MPTP to dopamine neurons in culture is reduced at high concentrations`, Neuroscience Letters, 79:65-72. Heikkila et al. (1984), `Behavioral Properties of GBR 12909, GBR 13069 and GBR 13098: Specific Inhibitors of Dopamine Uptake`, Euro J. Pharmacol., 103:241-248. Hofer and Barde (1988), `Brain-derived neurotrophic factor prevents neuronal death in vivo`, Nature, 331:261. Kozak (1987) `An analysis of 5'-nondocing sequences from 699 vertebrate messenger RNAs`, Nucleic Acids Res., 15:125-48. Leibrock et al. (1989), `Molecular cloning and expression of brain-derived neurotrophic factor`, Nature, 341:149-152. Lin et al. (1989), `Purification, Cloning, and Expression of Ciliary Neurotrophic Factor (CNTF)`, Science, 246:1023. Lo et al. (1990), `A Striatal-Derived Neurotrophic Factor (NTF): Relationship to Parkinson's Disease (PD)`, Soc. Neurosci. Abstr., 16:809. Maisonpierre et al. (1990), `Neurotrohin-3: A Neurotrophic Factor Related to NGF and BDNF`, Science, 247:1446-1451. Manthorpe et al. (1986), An Automated Colorimetric Microassay for Neuronotrophic Factors, Develop. Brain Res., 25:191-198. Nijima et al. (1990), `Enhanced survival of cultured dopamine neurons by treatment with soluble extracts from chemically deafferentiated striatum of adult rat brain`, Brain Res., 528:151-154. Schubert et al. (1974) `Clonal cell lines from the ra.sup..dagger. central nervous system`, Nature, 249:224-227. Thoenen and Edgar (1985), `Neurotrophic Factors`, Science, 229:238-242. Tresco et al. (1992), `Polymer Encapsulated Neurotransmitter Secreting Cells`, ASAIO, 38:17-23. Varon and Bunge (1979), `Trophic Mechanisms in the Peripheral Nervous System`, Ann. Rev. Neuroscience, 1:327-361. Williams, et al. (1986), `Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection`, Proc. Natl. Acad. Sci. USA, 83:9231. Winn et al. (1991), `Behavioral Recovery following Intrastriatal Implantation of Microencapsulated PC12 Cells`, Exper. Neurol., 113:322-329. Wurm, Florian M. (1990), `Integration, Amplification and Stability of Plasmid Sequences in CHO Cell Cultures`, Biologicals, 18:159-164. Bakhit et al. (1991) Brain Res. 560:76. Burt (1992) Biochem. and Biohphys. Res. Comm. 184:590. Creighton et al. (1984) Proteins: Structure & Molecular Properties (Freeman Co., New York) 39-41. Edgar et al. (1979) Experimental Cell Res. 121:353. Engele et al. (1989) Soc. Neuroscience Abstract 15:277. Gentry et al. (1989) Growth Inhibitory and Cytotoxic Polypeptides 143:154. Guenther et al. (1985) EMBO J. 4:1963. Houlgatte et al. (1989) J. Neuroscience Res. 24:143. Ito et al. (1986) Brain Res. 374:335. Kaisho et al. (1990) Febs Letters 266:187. Kim et al. (1991) The International J. Biochem. 23:1307. Kimura et al. (1990) Nature 348:257. Lin et al. (1993) Science 260:1131. Lin et al. (1993) Soc. Neuroscience Abstracts 19:651. Norrgren et al. (1980) Exp. Cell Res. 130:31. Purchio et al. (1987) Gene 60:175. Selingfreund et al. (1991) Proc. Natl. Acad. Sci. USA 88:3554. Sofer and Britton (1983) Biotechniques 1:198. Ullrich et al. (1983) Nature 303:821. Watson et al. (1987) in Molecular Biology of the Gene, 4th eds., (eds.) Benjamin Cummings Publishing Co. Amenlo Park, CA, p. 607. Jordan, J. et al., Eur. J. Neurosci., 9(8):1699-709, 1997, Abstract From Medline Only.* Hou, J.-G.G. et al., J. of Neurochemistry, 66(1):74-82, 1996. |
| PATENT PARENT CASE TEXT | This data is not available for free |
| PATENT CLAIMS |
What is claimed is: 1. A purified and isolated glial cell line-derived neurotrophic factor (GDNF) polypeptide encoded by a polynucleotide, wherein said polynucleotide: (a) comprises nucleotides 304 through 705 of SEQ ID NO:3 or nucleotides 105 through 506 of SEQ ID NO:5; or (b) encodes a polypeptide comprising an amino sequence set forth in SEQ ID NO:4 or SEQ ID NO:6; or (c) hybridizes to an oligonucleotide probe fully complementary to a polynucleotide encoding the amino acid sequence of SEQ ID NO:4 under conditions comprising hybridizing in 6X SSPE, 0.1% SDS and 30% formamide at 42.degree. C., followed by washing in 2X SSPE and 0.1% SDS at room temperature and twice in 0.1 x SSPE, 0.1% SDS preheated to 50.degree. C. and wherein said polypeptide promotes dopamine uptake in dopaminergic neorons; or (d) hybridizes to an olignucleotide probe fully complementary to a polynucleotide encoding the amino acid sequence of SEQ. ID. NO:6 under conditions comprising hybridizing in 6X SSPE and 0.1% SDS at 50.degree. C., followed by washing in 2X SSPE and 0.1% SDS at room temperature and twice in 0.1 x SSPE, 0.1% SDS preheated to 50.degree. C. and wherein said polypeptide promotes dopamine uptake in dopaminergic neurons. 2. A polypeptide according to claim 1 which is glycosylated. 3. A polypeptide according to claim 1 which is non-glycosylated. 4. A polypeptide according to claim 3, further comprising a methionine residue at the amino terminal when said polypeptide is expressed in a bacterial expression system. 5. A polypeptide according to claim 1 which is produced by recombinant technology or chemical synthesis. 6. A polypeptide according to claim 1 which is modified by attachment of one or more polymeric moieties. 7. A polypeptide according to claim 6, wherein the polymeric moiety is polyethylene glycol. 8. A purified and isolated glial cell line-derived neurotrophic factor polypeptide prepared according to the method comprising the steps of: (a) culturing a host cell under conditions suitable for the expression of glial cell line-derived neurotrophic factor polypeptide by said host cell; and (b) optionally, isolating said polypeptide; wherein said host cell expresses a polynucleotide encoding said polypeptide, wherein said polynucleotide; comprises nucleotides 304 through 705 of SEQ ID NO:3 or nucleotides 105 through 506 of SEQ ID NO:5; or (ii) encodes a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:4 or SEQ ID NO:6; or (iii) hybridizes to an oligonucleotide probe fully complementary to a polynucleotide encoding the amino acid sequence of SEQ ID NO:4 under conditions comprising hybridizing in 6X SSPE, 0.1% SDS and 30% formamide at 42.degree. C., followed by washing in 2X SSPE and 0.1% SDS at room temperature and twice in 0.1 x SSPE, 0.1% SDS preheated to 50.degree. C. and wherein said polypeptide promotes dopamine uptake in dopaminergic neurons; or (iv) hybridizes to an oligonucleotide probe fully complementary to a polynucleotide encoding the amino acid sequence of SEQ. ID. NO:6 under conditions comprising hybridizing in 6X SSPE and 0.1% SDS at 50.degree. C., followed by washing in 2X SSPE and 0.1% SDS at room temperature and twice in 0.1 x SSPE, 0.1% SDS preheated to 50.degree. C. and wherein said polypeptide promotes dopamine uptake in dopaminergic neurons. 9. A purified and isolated glial cell line-derived neurotrophic factor polypeptide comprising an amino acid sequence encoded by a nucleic acid sequence comprising nucleotides 304 through 705 of SEQ ID NO:3 or nucleotides 105 through 506 of SEQ ID NO:5 wherein said polypeptide promotes dopaminc uptake in dopaminergic neurons. 10. A purified and isolated glial cell line-derived neurotrophic factor polypeptide comprising an amino acid sequence of SEQ ID NO:4 or SEQ ID NO:6 wherein said polypeptide promotes dopamine uptake in dopaminergic neurons. 11. A purified and isolated glial cell line-derived neurotrophic factor polypeptide, comprising the amino acid sequence set forth in SEQ ID NO:6 wherein said polypeptide promotes dopamine uptake in dopaminergic neurons. 12. A purified and isolated glial cell line-derived neurotrophic factor polypeptide comprising an amino acid sequence encoded by a polynucleotide which hybridizes to an oligonucleotide probe fully complementary to a polynucleotide encoding the amino acid sequence of SEQ ID NO:4 under conditions comprising hybridizing in 6X SSPE, 0.1% SAS and 30% formamide at 42.degree. C., followed by washing in 2X SSPE and 0.1% SDS at room temperature and twice in 0.1 x SSPE, 0.1% SDS preheated to 50.degree. C. wherein said polypeptide promotes dopamine uptake in dopaminergic neurons. 13. A purified and isolated glial cell line-derived neurotrophic factor polypeptide comprising an amino acid sequence encoded by a polynucleotide which hybridizes to an oligonucleotide probe fully complementary to a polynucleotide encoding the amino acid sequence of SEQ. ID. NO:6 under conditions comprising hybridizing in 6X SSPE and 0.1% SDS at 50.degree. C., followed by washing in 2X SSPE and 0.1% SDS at room temperature and twice in 0.1X SSPE, 0.1% SDS preheated to 50.degree. C. and wherein said polypeptide promotes dopamine uptake in dopaminergic neutrons. 14. A polypeptide according to claim 8, 9, 10, 12 or 13 further comprising a methionine residue at the amino terminal when said polypeptide is produced by means of a bacterial expression system. 15. A polypeptide according to claim 8, 9, 10, 12, or 13 which is glycosylated. 16. A polypeptide according to claim 8, 9, 10, 12 or 13 which is non-glycosylated. 17. A polypeptide according to claim 8, 9, 10, 12 or 13 which is modified by attachment of one or more polymeric moieties. 18. A purified and isolated glial cell line-derived neurotrophic factor polypeptide of claim 8, 9, 10, 12 or 13 wherein said polypeptide is in the form of a dimer. 19. A composition comprising a glial cell line-derived neurotrophic factor polypeptide according to claim 1 or 8 and a pharmaceutically acceptable carrier or excipient. 20. The composition of claim 19 wherein said glial cell line-derived neurotrophic factor polypeptide is in the form of a dimer. 21. A composition comprising a glial cell line-derived neurotrophic factor polypeptide according to claim 8, 9, 10, 12 or 13 and a pharmaceutically acceptable carrier or excipient. 22. The composition of claim 21 wherein said glial cell line-derived neurotrophic factor polypeptide is in the form of a dimer. -------------------------------------------------------------------------------- |
| PATENT DESCRIPTION |
FIELD OF THE INVENTION The present invention relates to a neurotrophic factors and glial cell line-derived neurotrophic factor (GDNF) in particular. Also included within this invention are processes for purification of GDNF from natural sources and processes for cloning rat and human genes encoding GDNF, as well as the nucleic acid sequence of the rat and human genes that encode GDNF. The GDNF gene has been subcloned into an expression vector, and the vector used to express biologically active GDNF. In addition, this invention includes the use of GDNF for preventing and treating nerve damage and nerve related diseases such as Parkinson's disease. Antibodies to GDNF are disclosed, as well as methods for identifying members of the GDNF family of neurotrophic factors. And finally, methods are described for preventing or treating nerve damage by implanting into patients cells that secrete GDNF. BACKGROUND OF THE INVENTION Neurotrophic factors are natural proteins, found in the nervous system or in non-nerve tissues innervated by the nervous system, whose function is to promote the survival and maintain the phenotypic differentiation of nerve and/or glial cells (Varon and Bunge 1979 Ann. Rev. Neuroscience 1:327; Thoenen and Edgar 1985 Science 229:238). Because of this physiological role, neurotrophic factors may be useful in treating the degeneration of nerve cells and loss of differentiated function that occurs in a variety of neurodegenerative diseases. In order for a particular neurotrophic factor to be potentially useful in treating nerve damage, the class or classes of damaged nerve cells must be responsive to the factor. Different neurotrophic factors typically affect distinctly different classes of nerve cells. Therefore, it is advisable to have on hand a variety of different neurotrophic factors to treat each of the classes of damaged neurons that may occur with different forms of disease or injury. Neurotrophic factors can protect responsive neurons against a variety of unrelated insults. For example, the neurotrophic factor nerve growth factor (NGF) will rescue a significant portion of sensory neurons from death caused by cutting their axonal processes (Rich et al. 1987 J. Neurocytol 16:261; Otto et al. 1987 J. Neurosci 83:156), from ontogenetic death during embryonic development (Hamburger et al. 1984 J. Neurosci 4:767), and from damage caused by administration of taxol or cisplatin (Apfel et al. 1991 Ann Neurol. 29; 87). This apparent generality of protection has lead to the concept that if a neurotrophic factor protects responsive neurons against experimental damage, it may be useful in treating diseases that involve damage to those neurons in patients, even though the etiology may be unknown. A given neurotrophic factor, in addition to having the correct neuronal specificity, must be available in sufficient quantity to be used as a pharmaceutical treatment. Since neurotrophic factors are typically present in vanishingly small amounts in tissues (e.g., Hofer and Barde 1988 Nature 331:261; Lin et al. 1989 Science 246:1023), it would be inconvenient to prepare pharmaceutical quantities of neurotrophic factors directly from animal tissues. As an alternative, it would be desirable to locate the gene for a neurotrophic factor and use that gene as the basis for establishing a recombinant expression system to produce potentially unlimited amounts of the protein. The inventors of this application describe a method for screening biological samples for neurotrophic activity on the embryonic precursors of the substantia nigra dopaminergic neurons that degenerate in Parkinson's disease. This bioassay for identifying neurotrophic factors that may be useful in treating Parkinson's disease is based on an assay previously described (Friedman et al 1987 Neuro. Sci. Lett. 79:65-72, specifically incorporated herein by this reference) and implemented with modifications in the present invention. This assay was used to screen various potential sources for neurotrophic activity directed to dopaminergic neurons. The present invention describes the characterization of a new neurotrophic factor that was purified from one such source, the conditioned culture medium from a glioblastoma cell line, B49 (Schubert et al. 1974 Nature 249:224-27, specifically incorporated herein by this reference). The conditioned medium from this cell line was previously reported to contain dopaminergic neurotrophic activity (Bohn et al. 1988 Soc. Neurosci. Abs. 15:277). In this previous report, the source of the neurotrophic activity was not purified, characterized chemically, or shown to be the consequence of a single agent in the conditioned medium. Nerve damage is caused by conditions that compromise the survival and/or proper function of one or more types of nerve cells. Such nerve damage may occur from a wide variety of different causes, some of which are indicated below. Nerve damage may occur through physical injury, which causes the degeneration of the axonal processes and/or nerve cell bodies near the site of injury. Nerve damage may also occur because of temporary or permanent cessation of blood flow to parts of the nervous system, as in stroke. Nerve damage may also occur because of intentional or accidental exposure to neurotoxins, such as the cancer and AIDS chemotherapeutic agents cisplatinum and dideoxycytidine (ddC), respectively. Nerve damage may also occur because of chronic metabolic diseases, such as diabetes or renal dysfunction. Nerve damage may also occur because of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Amyotrophic Lateral Sclerosis (ALS), which result from the degeneration of specific neuronal populations. This application describes a novel neurotrophic factor. Neurotrophic factors are natural proteins that promote the normal functions of specific nerve cells and/or protect the same cells against a variety of different forms of damage. It is these properties that suggest that GDNF may be useful in treating various forms of nerve damage, including those forms indicated specifically above. Parkinson's disease is identified by a unique set of symptoms that include rigidity, bradykinesis, seborrhea, festination gait, flexed posture, salivation, and a "pil rolling" tremor. The disease is encountered in all races throughout the world, and the average age of onset is 60 years. After years of conflicting theories and controversy, a biochemical basis for Parkinson's disease has emerged as the major cause. (See, e.g., Bergman, 1990 Drug Store News, 12:IP19). Of significant importance to an understanding of Parkinson's disease are the areas of the brain known as the substantia nigra the basal angalia, and particularly, the corpus striatum. The substantia nigra, a bilaterally paired layer of pigmented gray matter in the mid-brain, is involved with dopamine transmission, while the normal basal ganglia function involves a series of interactions and feedback systems which are associated with the substantia nigra and mediated in part by dopamine, acetylcholine and other substances. In Parkinson's disease, there is a dysfunction in the dopaminergic activity of the substantia nigra which is caused by neuronal degeneration. This results in a state of dopamine deficiency and a shift in the balance of activity to a cholinergic predominance. Therefore, although there is no increase in the concentration of acetylcholine, the excitatory effects on the central nervous system (i.e., tremors) by this cholinergic mediator overwhelm the inhibiting effects of the depleted dopamine. The most effective treatment for Parkinson's disease to date is the oral administration of Levodopa. Levodopa penetrates the central nervous system and is enzymatically converted to dopamine in the basal ganglia. It is believed that beneficial effects of Levodopa are, therefore, in increasing the concentration of dopamine in the brain. Unfortunately, neither Levodopa or any of the less commonly utilized medications actually stem the progression of the disease which is caused by the degeneration of dopaminergic neurons. Other researchers have reported the existence of dopaminergic activity in various biological sources. In PCT publication WO91/01739 of Springer et al., a dopaminergic neurotrophic activity was identified in an extract derived from cells of the peripheral nervous system. The activity identified was not purified, but was attributed to a factor having a molecular weight of less than 10,000 daltons. The factor was isolated from rat sciatic nerve but is apparently not CNTF, which is also found in the nerve (Lin et al. 1989 Science 246:1023). In U.S. Pat. No. 5,017,735 of Appel et al., dopaminergic activity was identified in an extract from caudate-putamen tissue. Again, no factors giving rise to the activity were purified and the apparent molecular weight of the activity containing fractions was relatively small. See also, Niijima et al. 1990 Brain Res. 528:151-154 (chemically deafferented striatum of adult rat brain); Lo et al. 1990 Soc. Neurosci. Abstr., 16:809 (striatal-derived neurotrophic factor). In addition, other known neurotrophic factors have also been shown to have dopaminergic activity, e.g., Brain derived neurotrophic factor (BDNF), and acidic and basic Fibroblast Growth Factors. The GNDF of the present invention was isolated based on its ability to promote the functional activity and survival in cell culture of dopaminergic nerve cells isolated from the rat embryo mesencephalon. These dopaminergic nerve cells are the embryonic precursor of the dopaminergic nerve cells in the adult substantia nigra that degenerate in Parkinson's disease. Therefore, GDNF may be useful in reducing the neuronal degeneration that causes the symptoms of Parkinson's disease. Furthermore, GDNF may be useful in treating other forms of damage to or improper function of dopaminergic nerve cells in human patients. Such damage or malfunction may occur in schizophrenia and other forms of psychosis. Current treatments for such conditions often require drugs active at dopamine receptors, suggesting that improper function of the dopaminergic neurons innervating these receptor-bearing neuronal populations may be involved in the disease process. Based on previous experience with other neurotrophic factors, new forms of nerve damage that may be treated with GDNF will emerge as more is learned about the various types of nerve cells that are responsive to this neurotrophic factor. For example, nerve growth factor (NGF) only emerged as a potentially useful treatment for Alzheimer's disease when it was recently discovered that NFG acts as a neurotrophic factor for the basal forebrain cholinergic neurons that degenerate in Alzheimer's disease. (Williams, et al. 1986 Proc. Natl. Acad. Sci. USA 83:9231). Methods are provided in the present invention for determining other forms of nerve damage that may be usefully treated with GDNF. Patrick Aebischer and coworkers have described the use of semipermeable, implantable membrane devices that are useful as means for delivering drugs or medicaments in certain circumstances. For example, they have proposed the encapsulation of cells that secrete neurotransmitter factors, and the implantation of such devices into the brain of patients suffering from Parkinson's Disease. See, U.S. Pat. No. 4,892,538 of Aebischer et al.; U.S. Pat. No. 5,011,472 of Aebischer et al.; U.S. Pat. No. 5,106,627 of Aebischer et al.; PCT Application WO 91/10425; PCT Application WO 91/10470; Winn et al. 1991 Exper. Neurol. 113:322-329; Aebischer et al. 1991 Exper. Neurol. 111:269-275; and Tresco et al. 1992 ASAIO 38:17-23. SUMMARY OF THE INVENTION This invention relates to and claims substantially purified glial cell line-derived neurotrophic factor (GDNF). In one embodiment of this invention, substantially purified GDNF is obtained having a specific activity at least about 24,000 times greater than the specific activity of B49 conditioned medium. The substantially purified GDNF has a specific activity of at least about 12,000 TU/.mu.g. The substantially purified GDNF of the present invention has an apparent molecular weight of about 31-42 kD on non-reducing SDS-PAGE, and about 20-23 kD on reducing SDS-PAGE. The substantially purified GDNF has an amino terminal sequence comprised substantially of the amino acid sequence (SEQ ID NO:1): (Ser)-Pro-Asp-Lys-Gln-Ala-Ala-Ala-Leu-Pro-Arg-Arg-Glu-(Arg)-Asn-( )-Gln-Ala-Ala-Ala-Ala-(Ser)-Pro-(Asp)-(Asn). The amino acid sequence of mature and "pre-pro" forms of rat GDNF is as set forth in FIGS. 13 and 14 (SEQ ID NO:3 and SEQ ID NO:4). The amino acid sequence of mature human GDNF is as set forth in the underlined portion of FIG. 19 (SEQ ID NO:6). The amino acid sequence of the pre-pro form of human GDNF is set forth in FIGS. 19 (SEQ ID NO:5) and 22 (SEQ ID NO:8). One aspect of the invention is a method for obtaining purified GDNF comprising: 1) preparing a serum-free growth conditioned medium of B49 glioblastoma cells; 2) concentrating the conditioned medium; 3) performing heparin sepharose chromatography on the concentrated conditioned medium; 4) performing fast protein liquid chromatography on fractions obtained from said heparin sepharose chromatography; and 5) performing reverse-phase high-performance liquid chromatography on fractions obtained from said fast protein liquid chromatography. In one embodiment, the method of obtaining purified GDNF is further comprised of the steps: 6) subjecting fractions obtained by reverse-phase high performance liquid chromatography to preparative SDS-PAGE; and 7) performing reverse-phase high-performance liquid chromatography on fractions obtained by preparative SDS-PAGE. Also described is the cloning of the rat GDNF gene from a cDNA library prepared from the B49 cell line. The nucleic acid sequence encoding mature and pre-pro rat GDNF is set forth in FIG. 13 (SEQ ID NO:3). The method for obtaining a human gene coding for GDNF is also disclosed. The nucleic acid sequence encoding mature human GDNF is as set forth in FIG. 19 (SEQ ID NO:5). The nucleic acid sequence encoding the first 50 amino acids of the pre-pro segment of human GDNF is as set forth in FIG. 22 (SEQ ID NO:8). This invention also includes pharmaceutical compositions comprising an effective amount of purified GDNF in a pharmaceutically suitable carrier. Also described is a method for preventing or treating nerve damage which comprises administering to a patient in need thereof a therapeutically affective amount of GDNF. In preferred embodiments, the nerve damage is Parkinson's disease or damaged or improperly functioning dopaminergic nerve cells. In the preferred embodiment of this invention, GDNF is produced by recombinant DNA methods, utilizing the genes coding the GDNF as described herein. The present invention includes a vector for use in producing biologically active GDNF comprised of expression regulatory elements operatively linked to a nucleic acid sequence coding for mature or pre-pro GDNF, and a host cell transformed by such a vector. Also included is a recombinant DNA method for the production of GDNF comprising: subcloning a DNA sequence coding for GDNF into an expression vector which comprises the regulatory elements needed to express the DNA sequence; transforming a host cell with said expression vector; culturing the host cells under conditions for amplification of the vector and expression of GDNF; and harvesting the GDNF. A recombinant DNA method is described for the production of GDNF comprising: culturing the host cells of this invention under conditions for amplification of the vector and expression of GDNF; and harvesting the GDNF. This invention includes substantially purified antibodies that recognize GDNF. Also included is a method for preventing or treating nerve damage which comprises implanting cells that secrete glial cell line derived neurotrophic factor into the body of patients in need thereof. Finally, the present invention includes a device for preventing or treating nerve damage by implantation into a patient comprising a semipermeable membrane, and a cell that secretes GDNF encapsulated within said membrane and said membrane being permeable to GDNF and impermeable to factors from the patient detrimental to the cells. |
| PATENT EXAMPLES | This data is not available for free |
| PATENT PHOTOCOPY | Available on request |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |